OVERVIEW

A New Take on TYK2 Inhibitors: Bridging Gaps in Psoriatic Arthritis Management With Novel Targeted Therapies is organized by Answers in CME (AiCME).

Release Date: August 27, 2024
Expiration Date: August 26, 2025

Description:
In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies.

Educational Objectives:
Upon completion of this activity, participants should be better able to:

  • Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis
  • Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis
  • Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis
Credits

Accreditation
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS.

This CME activity is provided by Global Education Group. This activity is developed in collaboration with Answers in CME.

  • 0.5 AMA PRA Category 1 Credit™
  • TARGET AUDIENCE

    PhysicianPhysician AssistantCliniciansDermatologistsPrimary Care PhysiciansNurse PractitionersRheumatologistsImmunologists

    SPECIALITIES

    DermatologyRheumatology

    RELATED ONLINE COURSES